Published in Products

Automated vision-testing kiosks face concerns amid national expansion

This is editorially independent content
9 min read

With the launch of a new pilot program last month—and a new optical partnership just a few weeks ago—Eyebot is continuing to expand the national rollout of its automated vision testing technology.

Amidst these advancements, however, national and state optometric associations are raising patient safety and regulatory concerns over the self-administered tests.

Let’s begin with a look at Eyebot.

Founded in 2021 and funded by venture capitalists, the Boston, Massachusetts-based company has developed a self-serve, automated vision testing system built around a standalone kiosk.

Some details on this technology:

  • It’s designed as an automated visual assessment with on-screen instructions accessible via an intuitive interface
  • The touch-free vision test quickly captures measurements for eyeglass prescriptions through cameras and sensors
  • These measurements are interpreted by artificial intelligence (AI) to assess refractive errors and other vision characteristics (myopia, presbyopia, astigmatism, eye misalignment)
  • Following this automated evaluation process, the results are remotely reviewed and validated by a licensed eyecare provider (ECP) for final review
  • Once reviewed, a prescription is then finalized and generated

What type of information is collected during this process?

The test captures refraction, lensometry, and visual acuity (VA) information.

And regarding those remote ECPs: These experts (or their technicians) gather:

  • Multiple points of patient data (see above)
  • Any current eyeglass or contact lens settings
  • Past prescriptions
  • Personal characteristics (such as age, gender, and ethnicity)
    • To note: This test is designed for patients aged 18-64.

Once that information is collected, then a “well-tolerated prescription” is generated.

How long does the vision test take?

Around 90 seconds, according to Eyebot.

  • See the entire “Eyebot Rx Method” here—delivered via the company’s S1+ kiosk.

As for these prescriptions: They’re available either immediately or within 24 hours after the vision test.

So where can these kiosks be found?

The kiosks are reportedly already available at malls, universities, retail stores, and grocery chains across California, Connecticut, Massachusetts, and Rhode Island.

  • See here for details on Eyebot’s 2024 partnership with Zenni Optical to launch its kiosks in high-traffic locations around New England.
  • Click here for more on a new optical partnership Eyebot kicked off with The Framery at 1-800 Contacts in January.

And as Eyebot shared in December 2025, the company has begun piloting its kiosks in several Walmart Vision Centers and Sam’s Club Optical Centers across Pennsylvania to complement existing in-store and in-club optical services.

Is there a cost?

A $25 administrative fee applies (though Sam’s Club members are reportedly covered under their membership).

Now, how does this compare to a standard comprehensive eye exam?

Some reports have noted a few key differences between these two testing options, with one finding that an Eyebot-generated prescription is an exact match to one written by an ECP.

  • Pro: Speed, convenience, and accessibility versus an in-person eye exam
  • Con: The kiosk is unable to run medical tests such as measuring intraocular pressure (IOP), which is critical in identifying potential glaucoma risk

Has the test undergone any clinical validations?

Apparently so. According to Eyebot, its second-generation (Gen2) touch-free autorefractor technology is reportedly on par with gold-standard clinical systems—and has reportedly been tested in Institutional Review Board (IRB)-approved clinical studies involving +2.5K patients.

  • To note: Glance has reached out to the company for more details surrounding these IRB studies.

Next: Talk about those concerns you mentioned earlier.

This vision testing technology has drawn criticism from several state and national optometric organizations who have voiced their concerns to the Federal Trade Commission (FTC) and the FDA.

Among the issues highlighted: A need for the technology to undergo further assessments in order to safeguard patients’ health and privacy, as well as ensure Eyebot’s compliance with federal rules and regulations.

Go on …

While the AOA noted that Eyebot doesn’t advertise its kiosks as eye exams, “the language is similar enough that patients without prior knowledge may assume they are receiving the full breadth of services they receive during an in-person eye exam.”

  • See here for more on the organization’s stance.

Hone in on the patient safety portion of this.

Chris Wroten, OD, chair of the American Optometric Association's New Technology Committee, noted that the organization aims to embrace technology—not stifle innovation—but only that which advances patient care.

  • “Some technologies, whether intentional or unintentional, may endanger patients in the pursuit of profits,” he stated. “As new innovations roll out, there is an opportunity for standards of care to be compromised, so as the primary eye care profession, organized optometry must remain vigilant on behalf of our patients.”

Have any steps been taken to support this yet?

One notable change: The AOA revised its Policy Statement on Telemedicine in Optometry to include references to technology similar to the Eyebot.

“Direct-to-patient technology should not be used as a replacement for a comprehensive eye exam or for diagnostic eye, health or vision conditions,” the organization stated.

  • See page 9 of the updated policy statement for the exact wording.

And what’s the consensus from a state perspective?

This topic was actually at the center of a recent patient safety alert issued by the Pennsylvania Optometric Association (POA) last month.

  • Keep in mind: Pennsylvania currently has that Eyebot pilot program in place at several Walmart and Sams’ Clubs locations.

In this alert: The POA urged patients to consult with their local optometrist to ensure they get accurate information regarding the outcomes of any results they receive from what it referred to as “virtually unregulated, stand-alone vision kiosks.”

And the message they wanted to get across to patients?

As new direct-to-patient products enter the market—and as bold claims about what they can do are put forward—the organization noted:

  • “We want to make sure the public understands relevant warnings and disclaimers, especially when they can be obscured by marketing tactics and fine print.”

Duly noted. But has Eyebot said its vision tests are a replacement for eye exams?

Nope. In fact: The developers have emphasized that patients who undergo an Eyebot vision test should still see an ECP for detailed diagnosis and treatment plans—particularly for complex ocular conditions.

Additionally: Coverage of the technology noted that the kiosk test “obviously doesn’t replace a comprehensive eye exam by a trained optometrist,” and described it as a “first step—a ‘pre-check’ if you will” to help point patients in the right direction of seeking professional medical advice.

  • “But for routine checks or early detection, the Eyebot seems to be a game-changer in the world of vision care,” one report concluded.

So where does that leave us?

For now, Eyebot’s nation-wide expansion appears to still be underway—and it remains to be seen what (if anything) will arise from the AOA’s (and POA) recently voiced concerns and words of caution for patients.

And while the AOA noted that “telemedicine offers the opportunity for high-value, high-quality eye, health and vision care, expanding access for patients and improving implementation of care,” the organization added that “important criteria must be met to ensure these (technology) services meet the existing standard of care.”

  • If new technology contributes to care coordination, protects and promotes the doctor-patient relationship, and meets state and licensure and legal requirements, it will be welcomed into the optometry toolbox.”